Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

1.3K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.3K
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

2.2K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.2K
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

863
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
863
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

524
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
524
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

1.2K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.2K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

1.3K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stereotactic Radiosurgery (SRS) for Small Cell Lung Cancer (SCLC) brain metastases: a real-world UK tertiary centre experience.

The British journal of radiology·2026
Same author

Outbreak of post-parturient infectious pustular vulvovaginitis in a New Zealand dairy herd.

New Zealand veterinary journal·2025
Same author

Evaluating cervical screening coverage in Royal Navy personnel at sea (2016-2023): a case study on the limitations of digital surveillance.

BMJ military health·2025
Same author

Establishment and evaluation of a smoking cessation programme on the prevalence and intensity of smoking during a 6-month military deployment.

BMJ military health·2025
Same author

Investigation of post-vaccinal canine distemper involving the Rockborn-like strain in nine puppies in New Zealand.

New Zealand veterinary journal·2025
Same author

Diagnosis of <i>Mycoplasma columborale</i> in a fledgling kererū (<i>Hemiphaga novaeseelandiae</i>).

New Zealand veterinary journal·2024
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Feb 9, 2026

A Simplified Operation for the Endovascular Perforation Murine Model of Subarachnoid Hemorrhage
05:02

A Simplified Operation for the Endovascular Perforation Murine Model of Subarachnoid Hemorrhage

Published on: June 13, 2025

563

Perforated peptic ulcer; treated without operation

H TAYLOR

    Lancet (London, England)
    |October 29, 2010
    PubMed
    Summary

    No abstract available in PubMed .

    Keywords:
    PEPTIC ULCER/perforation

    More Related Videos

    Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
    04:09

    Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

    Published on: March 3, 2023

    3.8K
    Mouse Model of Pressure Ulcers After Spinal Cord Injury
    06:51

    Mouse Model of Pressure Ulcers After Spinal Cord Injury

    Published on: March 9, 2019

    10.1K

    Related Experiment Videos

    Last Updated: Feb 9, 2026

    A Simplified Operation for the Endovascular Perforation Murine Model of Subarachnoid Hemorrhage
    05:02

    A Simplified Operation for the Endovascular Perforation Murine Model of Subarachnoid Hemorrhage

    Published on: June 13, 2025

    563
    Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
    04:09

    Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

    Published on: March 3, 2023

    3.8K
    Mouse Model of Pressure Ulcers After Spinal Cord Injury
    06:51

    Mouse Model of Pressure Ulcers After Spinal Cord Injury

    Published on: March 9, 2019

    10.1K